Ann: Operational Update, page-2

• TACTI-002 patient recruitment update

• Six patients now enrolled and dosed in INSIGHT-004, 6 mg cohort complete

• Significant eftilagimod alpha clinical data expected in coming months:
o AIPAC Phase II - data expected in Q1 calendar year 2020
o TACTI-002 Phase II - data at SITC in Nov 2019 and in Q1 in 2020
o TACTI-mel Phase I - final safety data expected in H1 2020
o INSIGHT-004 Phase I - initial safety data expected in Q4 calendar year 2019

• Scale up to 2,000L for commercial manufacturing started

• Solid financial position following receipt of $7.4m GSK milestone payment, with expected cash runway at least to the end of calendar year 2020, well beyond above data catalysts